These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25786900)

  • 1. Small intestinal fungal overgrowth.
    Erdogan A; Rao SS
    Curr Gastroenterol Rep; 2015 Apr; 17(4):16. PubMed ID: 25786900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth.
    Jacobs C; Coss Adame E; Attaluri A; Valestin J; Rao SS
    Aliment Pharmacol Ther; 2013 Jun; 37(11):1103-11. PubMed ID: 23574267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)?
    Rao SSC; Tan G; Abdulla H; Yu S; Larion S; Leelasinjaroen P
    Clin Transl Gastroenterol; 2018 Apr; 9(4):146. PubMed ID: 29691369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fungal infections of the gastrointestinal tract].
    Maragkoudakis E; Realdi G; Dore MP
    Recenti Prog Med; 2005 Jun; 96(6):311-7. PubMed ID: 16078762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth.
    Strid H; Simrén M; Stotzer PO; Ringström G; Abrahamsson H; Björnsson ES
    Digestion; 2003; 67(3):129-37. PubMed ID: 12853724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.
    Pimentel M; Chow EJ; Lin HC
    Am J Gastroenterol; 2000 Dec; 95(12):3503-6. PubMed ID: 11151884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fungi in the intestine. Clinical significance].
    Kreisel W
    Praxis (Bern 1994); 1999 Jan; 88(1-2):5-10. PubMed ID: 10067100
    [No Abstract]   [Full Text] [Related]  

  • 8. Fungal infections of the gastrointestinal tract in the immunocompromised host: an update.
    Lamps LW; Lai KK; Milner DA
    Adv Anat Pathol; 2014 Jul; 21(4):217-27. PubMed ID: 24911247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early diagnosis of fungal infection in immunocompromised patients.
    Barnes RA
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i3-6. PubMed ID: 18063601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of immunocompromised patients with evidence of an invasive mycosis.
    Walsh TJ
    Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: coeliac disease and small intestinal bacterial overgrowth--is dysmotility the missing link?
    Mooney PD; Evans KE; Sanders DS
    Aliment Pharmacol Ther; 2014 Apr; 39(8):902-3. PubMed ID: 24635318
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
    Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW
    Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current drug therapy of systemic mycoses: a review.
    Yonga G
    East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the host on fungal infections.
    Perfect JR
    Am J Med; 2012 Jan; 125(1 Suppl):S39-51. PubMed ID: 22196208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Intestinal Transit Time Is Delayed in Small Intestinal Bacterial Overgrowth.
    Roland BC; Ciarleglio MM; Clarke JO; Semler JR; Tomakin E; Mullin GE; Pasricha PJ
    J Clin Gastroenterol; 2015 Aug; 49(7):571-6. PubMed ID: 25319735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal.
    Tursi A; Brandimarte G; Giorgetti G
    Am J Gastroenterol; 2003 Apr; 98(4):839-43. PubMed ID: 12738465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients.
    Schatz RA; Zhang Q; Lodhia N; Shuster J; Toskes PP; Moshiree B
    World J Gastroenterol; 2015 Apr; 21(15):4574-82. PubMed ID: 25914466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small intestinal bacterial overgrowth in the symptomatic elderly.
    Riordan SM; McIver CJ; Wakefield D; Bolin TD; Duncombe VM; Thomas MC
    Am J Gastroenterol; 1997 Jan; 92(1):47-51. PubMed ID: 8995936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triggers for driving treatment of at-risk patients with invasive fungal disease.
    Drgona L; Colita A; Klimko N; Rahav G; Ozcan MA; Donnelly JP
    J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii17-iii24. PubMed ID: 24155142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current therapeutic approaches to fungal infections in immunocompromised hematological patients.
    Pagano L; Caira M; Valentini CG; Posteraro B; Fianchi L
    Blood Rev; 2010 Mar; 24(2):51-61. PubMed ID: 20056300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.